United States-based pharmaceutical company Eton Pharmaceuticals Inc. has in-licensed United States commercialisation rights to HEMANGEOL oral solution from France-based Pierre Fabre Medicament Sas, according to a Globe Newswire report.

HEMANGEOL is an Orphan Drug indicated for treatment of proliferating infantile hemangioma requiring systemic therapy and represents the only FDA-approved treatment for this condition. Eton will begin commercialising HEMANGEOL in the United States from 1 May following Pierre Fabre's continued commercialisation through 30 April.

"As the only treatment for infantile hemangiomas that require systemic therapy, HEMANGEOL is a critical medication and a strong fit with Eton's orphan-focused commercial model," said Sean Brynjelsen, chief executive officer of Eton Pharmaceuticals. "With this acquisition and the recent approval of DESMODA, Eton has now achieved its long-held goal of ten commercial products. This major milestone reflects our continued progress toward building the largest rare disease portfolio in the United States."

Infantile hemangiomas are non-cancerous vascular tumours typically appearing in the first days or weeks of a newborn's life. In severe cases, infantile hemangiomas can lead to serious complications including loss of vision, trouble breathing or physical deformities requiring intervention with systemic therapy. Treatment with HEMANGEOL typically initiates between ages five weeks to five months and continues for approximately six months. An estimated 5,000 to 10,000 infants are treated with HEMANGEOL annually in the United States.

The transaction is expected to be accretive to 2026 earnings and will be financed with company cash. Eton plans to administer its Eton Cares Programme providing prescription fulfilment, insurance benefits investigation, educational support and financial assistance with $0 co-pay for qualifying patients.

Discover comprehensive details on Eton Pharmaceuticals' rare disease portfolio expansion strategy in the full story.